<DOC>
	<DOCNO>NCT00312988</DOCNO>
	<brief_summary>Determination total survival Topotecan Monotherapy , Topotecan + Etoposide Topotecan + Gemcitabine second-line therapy patient recurrent ovarian cancer .</brief_summary>
	<brief_title>Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine Ovarian Cancer Therapy</brief_title>
	<detailed_description>In Germany ovarian cancer belongs frequently form cancer female population . The prognosis woman platin refractory ovarian cancer bad . The median survival time amount less year . Especially palliative situation therapy regard efficacy well quality life need . Germany Topotecan approve since 1996 patient previous treatment platin , rare non-hematological side-effects make interesting palliative therapy . Since best result chemo-therapeutical treatment commonly obtain combination two cytostatic agent study test Topotecan Monotherapy two Topotecan combination . Both combination agent show efficacy alone solid cancer use Topotecan different mechanism result different main side effect . Total survival , remission rate , time ti progression quality life main criterion investigate .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Patient recurrent ovarian cancer Secondline chemotherapy &gt; = 18 year age ECOG &lt; = 2 ECOG &gt; 2 Patients one chemotherapy anamnesis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Ovarian cancer</keyword>
</DOC>